{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:32:39Z","timestamp":1773822759831,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.molmed.2024.04.004","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T22:09:41Z","timestamp":1714514981000},"page":"686-697","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7946-7145","authenticated-orcid":false,"given":"Reuben","family":"Ben-David","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Galsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Sfakianos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2024.04.004_bb0005","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","article-title":"Bladder cancer incidence and mortality: a global overview and recent trends","volume":"71","author":"Antoni","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0010","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1007\/s11255-022-03339-6","article-title":"Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study","volume":"54","author":"van Ginkel","year":"2022","journal-title":"Int. Urol. Nephrol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.05.009","article-title":"Outcomes for muscle-invasive bladder cancer with radical cystectomy or trimodal therapy in US veterans","volume":"30","author":"Kumar","year":"2021","journal-title":"Eur. Urol. open Sci."},{"key":"10.1016\/j.molmed.2024.04.004_bb0020","doi-asserted-by":"crossref","first-page":"7543","DOI":"10.1038\/s41598-018-26002-6","article-title":"Oncological outcome of primary and secondary muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"8","author":"Ge","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2024.04.004_bb0025","doi-asserted-by":"crossref","first-page":"E465","DOI":"10.5489\/cuaj.6907","article-title":"Radical cystectomy and perioperative chemotherapy in octogenarians with bladder cancer","volume":"15","author":"Savin","year":"2021","journal-title":"Can. Urol. Assoc. J."},{"key":"10.1016\/j.molmed.2024.04.004_bb0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2020.03.055","article-title":"European Association of Urology Guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 Guidelines","volume":"79","author":"Witjes","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0035","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0040","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.04.004_bb0045","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.eururo.2023.04.009","article-title":"Robot-assisted radical cystectomy with orthotopic neobladder reconstruction: techniques and functional outcomes in males","volume":"84","author":"Martini","year":"2023","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0050","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euros.2021.09.019","article-title":"The Studer neobladder: an established and reproducible technique for intracorporeal urinary diversion","volume":"35","author":"Lavall\u00e9e","year":"2022","journal-title":"Eur. Urol. open Sci."},{"key":"10.1016\/j.molmed.2024.04.004_bb0055","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1089\/end.2022.0248","article-title":"Detailed description of the Karolinska technique for intracorporeal Studer neobladder reconstruction","volume":"36","author":"Lavallee","year":"2022","journal-title":"J. Endourol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0060","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.eururo.2014.02.038","article-title":"Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review","volume":"66","author":"Ploussard","year":"2014","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1200\/JCO.2001.19.1.89","article-title":"Transurethral resection of muscle-invasive bladder cancer: 10-year outcome","volume":"19","author":"Herr","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0070","doi-asserted-by":"crossref","first-page":"8360","DOI":"10.1038\/s41598-018-26089-x","article-title":"Oncological outcomes, quality of life outcomes and complications of partial cystectomy for selected cases of muscle-invasive bladder cancer","volume":"8","author":"Ebbing","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2024.04.004_bb0075","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/bju.16299","article-title":"Comparison of urological outcomes and quality of life after pelvic exenteration: partial vs radical cystectomy","volume":"133","author":"van Kessel","year":"2024","journal-title":"BJU Int."},{"key":"10.1016\/j.molmed.2024.04.004_bb0080","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1200\/JCO.2014.57.5548","article-title":"Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233","volume":"32","author":"Mak","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0085","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2024.04.004_bb0090","doi-asserted-by":"crossref","first-page":"300.e7","DOI":"10.1016\/j.urolonc.2020.11.034","article-title":"The natural history of muscle-invasive bladder cancer in geriatric patients undergoing transurethral resection only: outcome and cost","volume":"39","author":"Degener","year":"2021","journal-title":"Urol. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0095","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/bju.14872","article-title":"The natural history of untreated muscle-invasive bladder cancer","volume":"125","author":"Martini","year":"2020","journal-title":"BJU Int."},{"key":"10.1016\/j.molmed.2024.04.004_bb0100","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41585-020-00404-6","article-title":"Defining cisplatin eligibility in patients with muscle-invasive bladder cancer","volume":"18","author":"Jiang","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.juro.2018.05.078","article-title":"Conservative management following complete clinical response to neoadjuvant chemotherapy of muscle invasive bladder cancer: contemporary outcomes of a multi-institutional cohort study","volume":"200","author":"Mazza","year":"2018","journal-title":"J. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.urology.2007.05.007","article-title":"Organ preservation for muscle-invasive bladder cancer by transurethral resection","volume":"70","author":"Leibovici","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.molmed.2024.04.004_bb0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.juro.2010.04.008","article-title":"Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer","volume":"184","author":"Solsona","year":"2010","journal-title":"J. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0120","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.euf.2016.12.005","article-title":"Absence of tumor on repeat transurethral resection of bladder tumor does not predict final pathologic T0 stage in bladder cancer treated with radical cystectomy","volume":"4","author":"Kukreja","year":"2018","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.molmed.2024.04.004_bb0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JCO.1996.14.1.119","article-title":"Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802","volume":"14","author":"Tester","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0130","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1634\/theoncologist.5-6-471","volume":"5","author":"Kaufman","year":"2000","journal-title":"Oncologist"},{"key":"10.1016\/j.molmed.2024.04.004_bb0135","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0360-3016(03)00718-1","article-title":"RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy","volume":"57","author":"Hagan","year":"2003","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.molmed.2024.04.004_bb0140","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.urology.2008.09.036","article-title":"Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy","volume":"73","author":"Kaufman","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.molmed.2024.04.004_bb0145","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S1470-2045(13)70255-9","article-title":"Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase","volume":"14","author":"Mitin","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0150","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1200\/JCO.1998.16.11.3576","article-title":"Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03","volume":"16","author":"Shipley","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0155","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.21037\/tau.2020.02.10","article-title":"Bladder-sparing protocols in the treatment of muscle-invasive bladder cancer","volume":"9","author":"Tholomier","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0160","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0165","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","article-title":"Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Coppin","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0170","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.04.004_bb0175","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.eururo.2022.04.017","article-title":"Chemoradiotherapy in muscle-invasive bladder cancer: 10-yr follow-up of the Phase 3 randomised controlled BC2001 trial","volume":"82","author":"Hall","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0180","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S1470-2045(23)00170-5","article-title":"Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis","volume":"24","author":"Zlotta","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0185","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.04.004_bb0190","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0195","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.juro.2014.03.078","article-title":"The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder","volume":"192","author":"Meyer","year":"2014","journal-title":"J. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0200","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2024.04.004_bb0205","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2023.41.6_suppl.438","article-title":"A phase II trial of risk-enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN)","volume":"41","author":"Geynisman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0210","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS4615","article-title":"A phase II study of gemcitabine plus cisplatin chemotherapy in patients with muscle-invasive bladder cancer with bladder preservation for those patients whose tumors harbor deleterious DNA damage response (DDR) gene alterations (Alliance A031701)","volume":"40","author":"Iyer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0215","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2020.07.016","article-title":"Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"79","author":"Becker","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0220","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2024.04.004_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2024.03.002","article-title":"Longitudinal tumor-informed circulating tumor DNA status predicts disease upstaging and poor prognosis for patients undergoing radical cystectomy","author":"Ben-David","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0230","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0235","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0240","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1158\/1078-0432.CCR-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2024.04.004_bb0245","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2018.04.029","article-title":"Multiparametric magnetic resonance imaging for bladder cancer: development of VI-RADS (vesical imaging-reporting and data system)","volume":"74","author":"Panebianco","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0250","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1148\/radiol.2019182506","article-title":"Multiparametric MRI for bladder cancer: validation of VI-RADS for the detection of detrusor muscle invasion","volume":"291","author":"Wang","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.molmed.2024.04.004_bb0255","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ajur.2021.06.001","article-title":"Validation of vesical imaging reporting and data system score for the diagnosis of muscle-invasive bladder cancer: a prospective cross-sectional study","volume":"9","author":"Ghanshyam","year":"2022","journal-title":"Asian J. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0260","doi-asserted-by":"crossref","first-page":"445","DOI":"10.21037\/tau.2020.02.16","article-title":"Evaluation of vesical imaging-reporting and data system (VI-RADS) scoring system in predicting muscle invasion of bladder cancer","volume":"9","author":"Liu","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0265","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40644-020-00304-3","article-title":"Evaluation of the value of the VI-RADS scoring system in assessing muscle infiltration by bladder cancer","volume":"20","author":"Wang","year":"2020","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.molmed.2024.04.004_bb0270","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2214\/AJR.20.22763","article-title":"Overview of VI-RADS in bladder cancer","volume":"214","author":"Pecoraro","year":"2020","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0275","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.eururo.2019.12.016","article-title":"Multiparametric magnetic resonance imaging as a noninvasive assessment of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer: preliminary findings from the Pure-01 study","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0280","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1200\/JCO.2016.69.2327","article-title":"Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic","volume":"35","author":"Kulkarni","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0285","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS589","article-title":"Study EV-302: a two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress)","volume":"40","author":"Van Der Heijden","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0290","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eururo.2016.12.002","article-title":"Clinical outcomes of patients with histologic variants of urothelial cancer treated with trimodality bladder-sparing therapy","volume":"72","author":"Krasnow","year":"2017","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0295","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.trecan.2019.05.011","article-title":"Treatment options and outcomes in nonmetastatic muscle invasive bladder cancer","volume":"5","author":"Ghandour","year":"2019","journal-title":"Trends Cancer"},{"key":"10.1016\/j.molmed.2024.04.004_bb0300","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.0849","article-title":"Comparison of sequential intravesical gemcitabine and docetaxel vs Bacillus Calmette-Gu\u00e9rin for the treatment of patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"McElree","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.molmed.2024.04.004_bb0305","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to Bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non-muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0310","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrurol.2015.58","article-title":"Expert consensus document: consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer","volume":"12","author":"Kamat","year":"2015","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0315","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.eururo.2021.12.005","article-title":"International Bladder Cancer Group consensus statement on clinical trial design for patients with Bacillus Calmette-Gu\u00e9rin-exposed high-risk non-muscle-invasive bladder cancer","volume":"82","author":"Roumigui\u00e9","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0320","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/S0022-5347(05)65756-4","article-title":"Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?","volume":"166","author":"Herr","year":"2001","journal-title":"J. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0325","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000499257","article-title":"Survival outcomes of early versus deferred cystectomy for high-grade non-muscle-invasive bladder cancer: a systematic review","volume":"14","author":"Wan","year":"2020","journal-title":"Curr. Urol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0330","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3390\/curroncol31020079","article-title":"BCG and alternative therapies to BCG therapy for non-muscle-invasive bladder cancer","volume":"31","author":"Lidagoster","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.molmed.2024.04.004_bb0335","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.euros.2023.04.013","article-title":"Bladder-sparing treatment in patients with Bacillus Calmette-Guerin\u2013unresponsive non-muscle-invasive bladder cancer: an analysis of long-term survival outcomes","volume":"53","author":"Tan","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"10.1016\/j.molmed.2024.04.004_bb0340","first-page":"39","article-title":"Systemic therapy in bladder preservation","volume":"41","author":"Girardi","year":"2023","journal-title":"Urol. Oncol. Semin. Orig. Investig."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424000923?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491424000923?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T02:48:21Z","timestamp":1720666101000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491424000923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":68,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1471491424000923"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2024.04.004","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel bladder-sparing approaches in patients with muscle-invasive bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2024.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}